18F-TFB PET/CT in Imaging Patients with Refractory or Metastatic Thyroid Cancer

Inclusion Criteria

• Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary and its respective variants)
• Patients should have tumors that are radiographically evident on PET, ultrasound, CT or MRI
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (or Karnofsky >= 60%)
• Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
• Hemoglobin >= 9 g/dl
• Platelets >= 100 x 10^9/L
• Albumin >= 2.5 g/dl
• Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional ULN unless it is related to the primary disease
• Creatinine =< 1.5 mg/dl OR calculated creatinine clearance (Cockcroft-Gault formula) >= 50 ml/min OR 24-hour urine creatinine clearance >= 50 ml/min
• Negative pregnancy test within 7 days prior to starting the study in premenopausal women; women of non-childbearing potential may be included without pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 year
• Fertile men and women must use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician; effective methods of contraception are defined as those, which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices); at the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance; (periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception)
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant, lactating, or breast feeding women
• Patients unable to follow a low iodine diet or requiring medication with high content in iodide (amiodarone)
• Patients who received iodinated intravenous contrast as part of a radiographic procedure within 3 months of study registration; those that have had iodinated intravenous contrast for CT imaging within this time frame may still be eligible if a urinary iodine analysis reveals that the excess iodine has been adequately cleared after the last intravenous contrast administration
• Unwillingness or inability to comply with study procedures